Pear Therapeutics’ Chapter 11 case closed on September 20, 2024, following asset sales and substantial consummation of its liquidation plan. The final decree Dkt. 840 authorized final creditor distributions and assigned the plan administrator trailing obligations, including distribution reconciliation, final tax filings and trust wind-down, without requiring the case to reopen.

Pear Therapeutics’ Chapter 11 case closed on September 20, 2024, following asset sales and substantial consummation of its liquidation plan. The final decree Dkt. 840 authorized final creditor distributions and assigned the plan administrator trailing obligations, including distribution reconciliation, final tax filings and trust wind-down, without requiring the case to reopen.